BioSpace News Archive

Continued safety from cohorts 1, 2 and 3 included in assessment by independent DSMB; Cohort 4 will focus on earlier stage dry-AMD patients; Additional functional data assessments are included in Cohort 4

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex® DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-Release Tablets, 1200 mg/60 mg).

Visterra, Inc. today announced that it will present new preclinical data on VIS410, a novel monoclonal antibody in development for treatment of hospitalized patients with influenza A, at the 2nd International Meeting on Respiratory Pathogens, at the Grand Copthorne Waterfront Hotel in Singapore, on March 7 - 9, 2018.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March

- WuXi NextCODE’s massively scalable genomics database management system and clinical and research applications will be available to Google Cloud Platform users - Google Cloud BigQuery, the open source DeepVariant and other tools will be integrated for use with the WuXi NextCODE platform - The companies plan to work on additional tools, capabilities and APIs going forward, to serve the global genomics community for the benefit of people worldwide

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 9:20 a.m., ET.

Bold approach helps a plan improve from 3 to 5 Stars for medication therapy management and comprehensive medication reviews in under 2 years

The Illinois Biotechnology Industry Organization announced that John Conrad has been named President & CEO of iBIO and the iBIO Institute.

Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2017 and provided an update on the company’s recent achievements.

Catasys, Inc.reported its financial results for the fourth quarter and year ended December 31, 2017.